Brain cancer treatment is evolving every day, and laser interstitial thermal therapy (LITT) is one of the most significant new advancements.
Six months after undergoing highly specialized surgery to remove an acoustic neuroma – Erika Dewling has a message for others.
A major phase III clinical trial has found that DCVax®-L, a dendritic cell brain tumor vaccine, can prolong the lives of patients diagnosed with new or recurrent glioblastomas.
Survival for patients with brain metastases from lung cancer is increasing – thanks to advancements in immunotherapy and personalized medications that target specific gene mutations, penetrate into the brain and have a high likelihood of success.
Certain lymphomas tend to enter the central nervous system and reach the brain. For high-risk patients, taking a novel and proactive approach to chemotherapy can reduce the likelihood of developing brain metastases by approximately 90%.
With new advances in breast cancer care, patients are living longer than ever before with a higher incidence of brain metastases.
The Glasser Brain Tumor Center is active in many clinical trials in our ongoing quest to enhance our patients’ lives. While all of the trials are inspiring, one of the most exciting is “SURVIVE” Phase 2B. We are the only site in New Jersey and one of the first three in the nation to participate in this trial for a potentially game-changing brain cancer vaccine.
Next-generation sequencing – similar to a search engine that combs through thousands of genes to find abnormalities in the single one that causes a patient’s cancer – is revolutionizing brain cancer care. An intimate understanding of a tumor’s mutations, or lack thereof, means more personalized and effective treatment plans.